辉瑞的新癌症治疗 使有攻击性的直肠癌病人的存活时间 增加了两倍 Pfizer's new cancer treatment doubles survival time for aggressive colorectal cancer patients.

根据晚期试验,从辉瑞公司获得的一种新的复方疗法使患强势直肠癌的患者的存活时间增加了一倍。 A new combination therapy from Pfizer has doubled the survival time for patients with an aggressive form of colorectal cancer, according to a late-stage trial. 这种治疗包括Braftovi与Cetuximab和标准的化疗,目标是BRAF V600E突变,在大约10%的直肠癌病例中发现。 The treatment, which includes Braftovi alongside cetuximab and standard chemotherapy, targets the BRAF V600E mutation, found in about 10% of colorectal cancer cases. 接受这种混合疗法的病人平均活30个月,而仅接受标准化疗的病人平均活15个月。 Patients who received this combination lived an average of 30 months compared to 15 months for those on standard chemotherapy alone. 治疗显示,死亡风险降低51%,并且得到良好的治疗,具有常见副作用,如恶心和腹泻。 The treatment showed a 51% lower risk of death and was well-tolerated, with common side effects like nausea and diarrhea. 美国食品和药物管理局已经对此疗法进行了快速批准. The FDA has granted fast-track approval for this therapy.